TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma
Keyword(s):
Phase 3
◽
2009 ◽
Vol 8
(4)
◽
pp. 184
◽
Keyword(s):